Personalized Neoantigen Cancer Vaccine for Patients With Solid Tumors

Clinical trial NCT06614140 · COMPLETED

Trial details

NCT number: NCT06614140
Sponsor: Seqker Biosciences, Inc.
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Cancer Solid Tumor, Adult

Start date: 2022-11-24
Primary completion: 2025-08-15
Enrollment: 8

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.